Swedish biotech company ready for phase III

Before the end of the year, Stockholm-based Pledpharma will initiate clinical trials with the company’s main candidate Pledox in 500 patients from Europe and the US.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Latest Top picks in English

Related articles